Cg Oncology (CGON) revenue and earnings history
Cg Oncology reported revenue of $4.04M for fiscal 2025 (year ended Dec 31, 2025), +254.7% on the year before, and net income of −$161M.
Over 2 years, from fiscal 2023 to fiscal 2025, revenue grew at a compound rate of +345.0% a year.
Revenue and net income, 3 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $4.04M+254.7% | −$191M | −$161M | −$132M | $134K | −$132M | $26.7M | — | — | $32.5M | $3M | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Cg Oncology (CGON) on OQRO.
Common questions
What was Cg Oncology's revenue in fiscal 2025?
$4.04M for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 27, 2026. That is +254.7% on fiscal 2024 ($1.14M).
How fast has Cg Oncology's revenue grown?
From $204K in fiscal 2023 to $4.04M in fiscal 2025: a compound annual growth rate of +345.0% over 2 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Cg Oncology been profitable?
It reported a net loss in 3 of the years shown (2023, 2024, 2025). The highest net income was −$48.6M in fiscal 2023.
Where these figures come from
The SEC’s companyfacts data: every figure Cg Oncology tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
